Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company Drug

Roche’s SKYSCRAPER-01 Study: Tiragolumab-Tecentriq Combo Misses Primary Endpoint in NSCLC

Fineline Cube Nov 27, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has reported an update on the phase III SKYSCRAPER-01...

Company Deals

Roche to Acquire Poseida Therapeutics in a USD 1.5 Billion Deal

Fineline Cube Nov 26, 2024

US-based clinical-stage biopharmaceutical company, Poseida Therapeutics (NASDAQ: PSTX), which specializes in donor-derived CAR-T cell therapies,...

Company Medical Device

Zymeworks and Jazz Pharmaceuticals’ Ziihera Gets Green Light for HER2+ BTC Treatment

Fineline Cube Nov 26, 2024

Partners Zymeworks Inc. (NASDAQ: ZYME) and Jazz Pharmaceuticals, Inc. have received accelerated approval from the...

Company Deals

Lakeside Holding’s Hupan Pharmaceutical Partners with Sinopharm Group Hubei for Supply Chain Services

Fineline Cube Nov 26, 2024

US-based supply chain solution provider Lakeside Holding Limited (NASDAQ: LSH), which specializes in the Asian...

Policy / Regulatory

NHSA to Announce NRDL Adjustment Results at November 28th Press Conference

Fineline Cube Nov 26, 2024

The National Healthcare Security Administration (NHSA) will unveil the results of the negotiation and price...

Policy / Regulatory

NMPA and Local Governments Streamline Drug Approval Processes in China

Fineline Cube Nov 26, 2024

The National Medical Products Administration (NMPA) has released a notification regarding the pilot work for...

Company Deals

Adcendo ApS Secures Oversubscribed USD135 Million Series B Financing to Advance ADC Pipeline

Fineline Cube Nov 26, 2024

Danish antibody drug conjugate (ADC) specialist, Adcendo ApS, has announced the completion of an oversubscribed...

Company Medical Device

Abbott Laboratories Expands Structural Heart Portfolio with TAVI Balloon-Expandable System

Fineline Cube Nov 26, 2024

US-based Abbott Laboratories (NYSE: ABT) has announced the successful application of its transcatheter aortic valve...

Company Drug

Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH

Fineline Cube Nov 26, 2024

US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced positive interim analysis results...

Company Deals

Boston Scientific Corporation to Acquire Intera Oncology Inc., Expanding Cancer Treatment Portfolio

Fineline Cube Nov 26, 2024

US-based medical device giant Boston Scientific Corporation (NYSE: BSX) has announced a definitive acquisition agreement...

Company Drug

Nasal-Phyto Pharmaceutical Receives FDA Clearance for First-Ever Olfactory Drug-Device Combo

Fineline Cube Nov 26, 2024

China-based Nasal-Phyto Pharmaceutical Technology Group Co., Ltd has announced receiving clinical clearance from the US...

Company Drug

GSK’s Blenrep BLA for Multiple Myeloma Treatments Accepted by FDA for Review

Fineline Cube Nov 26, 2024

UK-based pharmaceutical company GlaxoSmithKline (GSK; NYSE: GSK) has announced that the US Food and Drug...

Company Drug

Insilico Medicine Gets FDA Approval for Clinical Study of ENPP1 Inhibitor ISM5939

Fineline Cube Nov 26, 2024

China’s generative artificial intelligence (AI)-driven biotech company, Insilico Medicine, has announced that it has received...

Company Drug

SCG Cell Therapy Presents Phase I Data for HBV-Specific TCR-T Therapy SCG101 at AASLD 2024

Fineline Cube Nov 26, 2024

SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has announced...

Company Drug

Shenzhen Kangtai Begins Phase I Clinical Trial for 20-Valent Pneumococcal Vaccine

Fineline Cube Nov 26, 2024

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the enrollment of the...

Company Drug

Sichuan Kelun-Biotech Receives NMPA Clearance for SKB501 Clinical Trial in Solid Tumors

Fineline Cube Nov 26, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received clearance from...

Company Drug

Lepu Medical Technology Gains NMPA Approval for Obesity and Diabetes Treatments MWN109 and MWN105

Fineline Cube Nov 26, 2024

China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease...

Company Deals

3SBio Inc. Secures Licensing Deal with Sunshine Lake Pharma for Clifutinib Commercialization

Fineline Cube Nov 26, 2024

China-based 3SBio Inc. (HKG: 1530) has announced a licensing deal with fellow Chinese firm Sunshine...

Company Drug

Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH

Fineline Cube Nov 26, 2024

US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced favorable interim analysis results...

Company Deals

Hubei Guangji Pharmaceutical Expands Ex-Hospital Market Presence with New Partnerships

Fineline Cube Nov 26, 2024

China-based Hubei Guangji Pharmaceutical Co., Ltd. (SHE: 000952) is poised to establish a strong presence...

Posts pagination

1 … 254 255 256 … 661

Recent updates

  • Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer
  • Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations
  • BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year
  • Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio
  • Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Others

Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations

Company

BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year

Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.